PURPOSE: The right ventricle (RV) has a high capacity to adapt to pressure or volume overload before failing. However, the mechanisms of RV adaptation, in particular RV energetics, in patients with pulmonary hypertension (PH) are still not well understood. We aimed to evaluate RV energetics including RV oxidative metabolism, power and efficiency to adapt to increasing pressure overload in patients with PH using (11)C-acetate PET. METHODS: In this prospective study, 27 patients with WHO functional class II/III PH (mean pulmonary arterial pressure 39.8 ± 13.5 mmHg) and 9 healthy individuals underwent (11)C-acetate PET. (11)C-acetate PET was used to simultaneously measure oxidative metabolism (k mono) for the left ventricle (LV) and RV. LV and RV efficiency were also calculated. RESULTS: The RV ejection fraction in PH patients was lower than in controls (p = 0.0054). There was no statistically significant difference in LV k mono (p = 0.09). In contrast, PH patients showed higher RV k mono than did controls (0.050 ± 0.009 min(-1) vs. 0.030 ± 0.006 min(-1), p < 0.0001). PH patients exhibited significantly increased RV power (p < 0.001) and hence increased RV efficiency compared to controls (0.40 ± 0.14 vs. 0.017 ± 0.12 mmHg·mL·min/g, p = 0.001). CONCLUSION: The RV oxidative metabolic rate was increased in patients with PH. Patients with WHO functional class II/III PH also had increased RV power and efficiency. These findings may indicate a myocardial energetics adaptation response to increasing pulmonary arterial pressure.
PURPOSE: The right ventricle (RV) has a high capacity to adapt to pressure or volume overload before failing. However, the mechanisms of RV adaptation, in particular RV energetics, in patients with pulmonary hypertension (PH) are still not well understood. We aimed to evaluate RV energetics including RV oxidative metabolism, power and efficiency to adapt to increasing pressure overload in patients with PH using (11)C-acetate PET. METHODS: In this prospective study, 27 patients with WHO functional class II/III PH (mean pulmonary arterial pressure 39.8 ± 13.5 mmHg) and 9 healthy individuals underwent (11)C-acetate PET. (11)C-acetate PET was used to simultaneously measure oxidative metabolism (k mono) for the left ventricle (LV) and RV. LV and RV efficiency were also calculated. RESULTS: The RV ejection fraction in PH patients was lower than in controls (p = 0.0054). There was no statistically significant difference in LV k mono (p = 0.09). In contrast, PH patients showed higher RV k mono than did controls (0.050 ± 0.009 min(-1) vs. 0.030 ± 0.006 min(-1), p < 0.0001). PH patients exhibited significantly increased RV power (p < 0.001) and hence increased RV efficiency compared to controls (0.40 ± 0.14 vs. 0.017 ± 0.12 mmHg·mL·min/g, p = 0.001). CONCLUSION: The RV oxidative metabolic rate was increased in patients with PH. Patients with WHO functional class II/III PH also had increased RV power and efficiency. These findings may indicate a myocardial energetics adaptation response to increasing pulmonary arterial pressure.
Authors: H Laine; C Katoh; M Luotolahti; H Yki-Järvinen; I Kantola; A Jula; T O Takala; U Ruotsalainen; H Iida; M Haaparanta; P Nuutila; J Knuuti Journal: Circulation Date: 1999-12-14 Impact factor: 29.690
Authors: Paul Knaapen; Tjeerd Germans; Juhani Knuuti; Walter J Paulus; Pieter A Dijkmans; Cornelis P Allaart; Adriaan A Lammertsma; Frans C Visser Journal: Circulation Date: 2007-02-20 Impact factor: 29.690
Authors: Yeun Ying Wong; Nico Westerhof; Gerrina Ruiter; Mark Lubberink; Pieter Raijmakers; Paul Knaapen; J Tim Marcus; Anco Boonstra; Adriaan A Lammertsma; Willem J van der Laarse; Anton Vonk-Noordegraaf Journal: Eur J Heart Fail Date: 2011-10-20 Impact factor: 15.534
Authors: H Ukkonen; M Saraste; J Akkila; J Knuuti; M Karanko; H Iida; P Lehikoinen; K Någren; L Lehtonen; L M Voipio-Pulkki Journal: Clin Pharmacol Ther Date: 2000-11 Impact factor: 6.875
Authors: Andrew M Kates; Pilar Herrero; Carmen Dence; Pablo Soto; Muthayyah Srinivasan; Deborah G Delano; Ali Ehsani; Robert J Gropler Journal: J Am Coll Cardiol Date: 2003-01-15 Impact factor: 24.094
Authors: Yeun Ying Wong; Pieter Raijmakers; Jasmijn van Campen; Willem J van der Laarse; Paul Knaapen; Mark Lubberink; Gerrina Ruiter; Anton Vonk Noordegraaf; Adriaan A Lammertsma Journal: J Nucl Med Date: 2013-06-04 Impact factor: 10.057
Authors: Ali Ahmadi; Jennifer M Renaud; Steven Promislow; Ian G Burwash; Girish Dwivedi; Ran Klein; Jason G E Zelt; Robert A deKemp; Rob S Beanlands; Lisa M Mielniczuk Journal: J Nucl Cardiol Date: 2020-05-07 Impact factor: 5.952
Authors: Umberto Annone; Pier P Bocchino; Walter G Marra; Fabrizio D'Ascenzo; Corrado Magnino; Antonio Montefusco; Pierluigi Omedè; Franco Veglio; Alberto Milan; Gaetano M de Ferrari Journal: Pulm Circ Date: 2019-12-27 Impact factor: 3.017
Authors: Anne-Marie C Koop; Guido P L Bossers; Mark-Jan Ploegstra; Quint A J Hagdorn; Rolf M F Berger; Herman H W Silljé; Beatrijs Bartelds Journal: J Am Heart Assoc Date: 2019-10-28 Impact factor: 5.501